The Amgen Tour of California is America's largest road cycling race and will bring the drama and excitement of professional cycling to California for the 13th consecutive year. The Tour de France-style seven-stage men's event, created and presented by AEG, will challenge the world's top professional cycling teams to compete along a demanding course from May 13–19, 2018.
The Amgen Women's Race empowered with SRAM will run May 17–19 as the North American stage race of the UCI Women's World Tour.
About Breakaway from Heart Disease™
Breakaway from Heart Disease™ encourages Americans to take charge of their risk of heart disease and represents a partnership between Amgen and the American Heart Association. This initiative is dedicated to empowering everyone to have a plan for good heart health through diagnostic screenings as well as information and tools related to physical activity and healthy eating. Amgen also has a partnership with the bike company Schwinn to encourage heart healthy activities like bike riding.
About Breakaway from Cancer®
The Breakaway from Cancer® initiative, founded in 2005, aims to increase awareness of important resources available to people affected by cancer – from prevention through survivorship. Breakaway from Cancer® is a collaboration between Amgen and four independent nonprofit partner organizations that offer a broad range of free support services complementing those provided by a patient's team of healthcare professionals.
To view more videos about Amgen and its commitment to science, patients, and our communities, visit our YouTube channel.
For more information about Breakaway from Heart Disease™, visit BreakawayFromHeartDisease.com or follow Breakaway from Heart Disease™ on Twitter, Facebook and Instagram.
For more information about Breakaway from Cancer®, visit BreakawayFromCancer.com or follow Breakaway from Cancer® on Twitter, Facebook and Instagram.
For more information about this year's Amgen Tour of California route and team rosters are available at AmgenTourofCalifornia.com.
